Shu Li

发表

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

A. Gottlieb, U. Chaudhari, Lisa D Mulcahy, 2003, Journal of the American Academy of Dermatology.

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

A. Gottlieb, M. Bala, A. Menter, 2004, Journal of the American Academy of Dermatology.

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

A. Gottlieb, S. Feldman, A. Menter, 2007, Journal of the American Academy of Dermatology.

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials

C. Griffiths, P. Foley, K. Gordon, 2018, JAMA dermatology.

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

A. Kimball, K. Papp, Y. Wasfi, 2017, Journal of the American Academy of Dermatology.

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

F. Nestle, K. Reich, C. Griffiths, 2008, Journal of the American Academy of Dermatology.

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

B. Strober, M. Lebwohl, C. Leonardi, 2012, Journal of the American Academy of Dermatology.

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

M. Lebwohl, K. Papp, K. Reich, 2010, Journal of the American Academy of Dermatology.

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

A. Armstrong, K. Reich, A. Blauvelt, 2019, The Lancet.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

K. Reich, K. Gordon, Y. Wasfi, 2015, The New England journal of medicine.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

M. Lebwohl, K. Papp, K. Reich, 2008, The Lancet.

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.

M. Curran, Katherine Li, C. C. Huang, 2016, The Journal of investigative dermatology.

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.

A. Paller, A. Menter, L. Eichenfield, 2015, Journal of the American Academy of Dermatology.

Kavanaugh, A. et al. (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT

A. Gottlieb, P. Rahman, I. McInnes, 2014 .

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

A. Gottlieb, P. Rahman, I. McInnes, 2014, Annals of the rheumatic diseases.

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

A. Gottlieb, M. Bala, A. Menter, 2008, Journal of drugs in dermatology : JDD.

Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials

A. Gottlieb, A. Menter, K. Reich, 2007 .

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial

A. Armstrong, Chenglong Han, L. Puig, 2018, The Journal of dermatological treatment.

Clinical features of inflammatory bowel disease combined with severe complications: a retrospective study of hospitalized patients

Shirong Li, P. Jin, J. Sheng, 2019 .

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

K. Reich, K. Gordon, S. Youn, 2019, The Journal of dermatology.

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.

A. Armstrong, E. Muñoz-Elías, K. Reich, 2019, The Journal of investigative dermatology.

Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis - Guselkumab

Amarnath Sharma, Honghui Zhou, Shu Li, 2019, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases.

Amphiregulin from Basophils Ampliﬁes Basophil-Mediated Chronic Skin Inﬂammation

Honghui Zhou, Shu Li, J. Marini, 2019 .

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).

Jee-ho Choi, T. Tsai, Shu Li, 2011, Journal of dermatological science.

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

F. Nestle, J. Ortonne, K. Papp, 2005, The Lancet.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

A. Gottlieb, A. Menter, A. Kavanaugh, 2009, The Lancet.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

A. Gottlieb, P. Rahman, I. McInnes, 2014, Annals of the rheumatic diseases.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

A. Gottlieb, P. Rahman, I. McInnes, 2013, The Lancet.

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

A. Gottlieb, P. Rahman, I. McInnes, 2016, Annals of the rheumatic diseases.

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial

A. Gottlieb, P. Rahman, I. McInnes, 2015, Arthritis care & research.

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

K. Papp, Chenglong Han, M. Song, 2018, SKIN The Journal of Cutaneous Medicine.

Impact of withdrawal and retreatment on immunogenicity of guselkumab in patients with moderate-to-severe plaque psoriasis

M. Song, Y. Wasfi, Honghui Zhou, 2018, Journal of the American Academy of Dermatology.

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

A. Armstrong, K. Reich, P. Foley, 2017, Journal of the American Academy of Dermatology.

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis

A. Gottlieb, P. Rahman, I. McInnes, 2016, Arthritis care & research.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

A. Kimball, K. Papp, K. Gordon, 2008, The Lancet.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

B. Strober, A. Menter, P. C. van de Kerkhof, 2010, The New England journal of medicine.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

A. Kimball, V. Ho, K. Papp, 2012, Journal of the American Academy of Dermatology.

Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.

A. Kimball, A. Armstrong, K. Papp, 2019, Journal of the American Academy of Dermatology.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

A. Kimball, K. Papp, A. Blauvelt, 2018, Journal of drugs in dermatology : JDD.

Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy.

F. Nestle, J. Ortonne, K. Papp, 2005 .

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study

L. Ferris, Chenglong Han, Shu Li, 2020, The Journal of dermatological treatment.

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies

K. Reich, Chenglong Han, K. Gordon, 2019, Journal of Psoriasis and Psoriatic Arthritis.

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.

Honghui Zhou, Shu Li, J. Marini, 2019, The Journal of investigative dermatology.

Ritchlin, C. et al. (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double

A. Gottlieb, P. Rahman, I. McInnes, 2014 .

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

M. Bala, F. Nestle, K. Reich, 2007, EJD. European journal of dermatology.

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

M. Lebwohl, C. Griffiths, K. Reich, 2011, The British journal of dermatology.

A. Gottlieb, P. Rahman, I. McInnes, 2014, Annals of the rheumatic diseases.

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study

A. Kimball, K. Papp, K. Gordon, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

A. Kimball, K. Papp, K. Gordon, 2012, The British journal of dermatology.

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

M. Song, Y. Wasfi, T. Tsai, 2018, The British journal of dermatology.

Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study

A. Kimball, K. Papp, Chenglong Han, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Infliximab safety experience: Data from clinical trials in patients with psoriatic disease

F. Nestle, K. Gordon, Shu Li, 2006 .